All Stories

  1. ROCK2 Inhibition Underlying the Anticancer Effects of Dobutamine: A Novel Proposed Mechanism
  2. Computer-aided discovery of CDK16 inhibitors: a docking-augmented machine learning regression modelling approach
  3. Arbutus andrachne Extracts Exhibit In Vitro Neuraminidase (N9) Inhibitory Activity: A Potential Herbal Strategy Against Avian Influenza
  4. Recent developments in pharmacophore-based modeling of Ca 2+/ Calmodulin-dependent protein kinase II delta (CaMkIIδ) inhibitors for heart failure therapy
  5. Innovative integration of molecular docking and machine learning for drug discovery: from virtual screening to nanomolar inhibitors
  6. Synthesis, and evaluation of novel low nanomolar isoindigo-based RET kinase inhibitors
  7. Deep learning model for activity cliffs prediction: a comprehensive approach to protein kinase inhibitors
  8. Novel diazepine-carbamate derivatives as dual-acting butyrylcholinesterase inhibitors and antioxidants for Alzheimer’s disease
  9. Identification and evaluation of potent AAK1 inhibitors through structure-based pharmacophores, virtual screening and bioassay screening
  10. Computational discovery of novel PI3KC2α inhibitors using structure-based pharmacophore modeling, machine learning and molecular dynamic simulation
  11. Design, synthesis and biological evaluation of monoglyceride lipase inhibitors guided by dipeptidyl peptidase IV inhibitors
  12. Discovery of New HER2 Inhibitors via Computational Docking, Pharmacophore Modeling, and Machine Learning
  13. Recognition-induced destabilization: controlled release from molecularly imprinted chitosan nanoparticles via specific, non-catalytic enzyme recognition
  14. Quinoline and coumarin isoxazole derivatives: synthesis, antitumor evaluation and molecular docking studies with Bcl-2
  15. Advances in the design and discovery of next-generation janus kinase-2 (JAK2) inhibitors for the treatment of myeloproliferative neoplasms
  16. Docking-guided exploration of the anti-flt3 potential of isoindigo derivatives towards potential treatments of acute myeloid leukemia
  17. Synthesis of novel benzothieno-[3,2’-f][1,3] oxazepines and their isomeric 2-oxo-2H-spiro[benzothiophene-3,3’-pyrrolines] via 1,4-dipolar cycloaddition reaction and their evaluation as cytotoxic anticancer leads
  18. Protein characteristics substantially influence the propensity of activity cliffs among kinase inhibitors
  19. Preparation of novel shell-ionotropically crosslinked micelles based on hexadecylamine and tripolyphosphate for cancer drug delivery
  20. Ligand-based pharmacophore modeling and machine learning for the discovery of potent aurora A kinase inhibitory leads of novel chemotypes
  21. Structure‐Based Approaches for the Prediction of Alzheimer's Disease Inhibitors: Comparative Interactions Analysis, Pharmacophore Modeling and Molecular Dynamics Simulations
  22. Synthesis and antitumor activity of model cyclopentene-[g]annelated isoindigos
  23. Discovery of potent maternal embryonic leucine zipper kinase (MELK) inhibitors of novel chemotypes using structure-based pharmacophores
  24. Synthesis, anticancer evaluation and docking studies of novel adamantanyl-1,3,4-oxadiazol hybrid compounds as Aurora-A kinase inhibitors
  25. Tableting-induced mechanochemical matrix crosslinking: Towards non-disintegrating chitosan-based sustained delivery tablets
  26. Computational workflow for discovering small molecular binders for shallow binding sites by integrating molecular dynamics simulation, pharmacophore modeling, and machine learning: STAT3 as case study
  27. Augmenting bioactivity by docking‐generated multiple ligand poses to enhance machine learning and pharmacophore modelling: discovery of new TTK inhibitors as case study
  28. Development of phosphoinositide 3-kinase delta (PI3Kδ) inhibitors as potential anticancer agents through the generation of ligand-based pharmacophores and biological screening
  29. Asenapine as a Potential Lead Inhibitor against Central Ca2+/Calmodulin-Dependent Protein Kinase II: Investigation by Docking Simulation and Experimental Validation
  30. Discovery of new STAT3 inhibitors as anticancer agents using ligand-receptor contact fingerprints and docking-augmented machine learning
  31. Molecular docking, molecular dynamics simulations and in vitro screening reveal cefixime and ceftriaxone as GSK3β covalent inhibitors
  32. A Click Synthesis, Molecular Docking and Biological Evaluation of 1,2,3-triazoles-benzoxazepine hybrid as potential anticancer agents
  33. Dipeptidyl Peptidase-IV Blockers Potently Inhibit Monoglyceride Lipase: Investigation By Docking Studies And In Vitro Bioassay
  34. Ligand-based Modeling of CXC Chemokine Receptor 4 and Identification of Inhibitors of Novel Chemotypes as Potential Leads towards New Anti- COVID-19 Treatments
  35. Biological Evaluation and Reverse Pharmacophore Mapping of Innovative Bis-Triazoles as Promising Anticancer Agents
  36. Pharmacophore Modeling of Targets Infested with Activity Cliffs via Molecular Dynamics Simulation Coupled with QSAR and Comparison with other Pharmacophore Generation Methods: KDR as Case Study
  37. Discovery of new PKN2 inhibitory chemotypes via QSAR-guided selection of docking-based pharmacophores
  38. Vitamin B12 binding to mutated human transcobalamin, in-silico study of TCN2 alanine scanning and ClinVar missense mutations/SNPs
  39. The study aimed to assess side effects among Arab communities after receiving a COVID-19 vaccine.
  40. Activity Cliffs As Protein-Related Phenomenon: Investigation Using Machine Learning Against Numerous Protein Kinases
  41. Exploiting activity cliffs for building pharmacophore models and comparison with other pharmacophore generation methods: sphingosine kinase 1 as case study
  42. Discovery of new Cdc2-like kinase 4 (CLK4) inhibitors via pharmacophore exploration combined with flexible docking-based ligand/receptor contact fingerprints and machine learning
  43. Discovery of new potent lysine specific histone demythelase-1 inhibitors (LSD-1) using structure based and ligand based molecular modelling and machine learning
  44. Design and Synthesis of New JAK1 Inhibitors based on Sulfonamide- Triazine Conjugates
  45. Inhibition of protein kinases by proton pump inhibitors: computational screening and in vitro evaluation
  46. Inhibition of aggregation of amyloid-β through covalent modification with benzylpenicillin; potential relevance to Alzheimer's disease
  47. Docking-generated multiple ligand poses for bootstrapping bioactivity classifying Machine Learning: Repurposing covalent inhibitors for COVID-19-related TMPRSS2 as case study
  48. Structure-Based Discovery and Bioactivity Evaluation of Novel Aurora-A Kinase Inhibitors as Anticancer Agents via Docking-Based Comparative Intermolecular Contacts Analysis (dbCICA)
  49. Comprehensive Structural and Molecular Comparison of Spike Proteins of SARS-CoV-2, SARS-CoV and MERS-CoV, and Their Interactions with ACE2
  50. Pharmacophore modeling of JAK1: A target infested with activity-cliffs
  51. Elaboration of Novel TTK1 Inhibitory Leads via QSAR-Guided Selection of Crystallographic Pharmacophores Followed By In vitro Assay
  52. Ligand Based Pharmacophore Modeling Followed by Biological Screening Lead to Discovery of Novel PDK1 Inhibitors as Anticancer Agents
  53. Design and Synthesis of New Sulfonamides-Based Flt3 Inhibitors
  54. Discovery of new JNK3 inhibitory chemotypes via QSAR-Guided selection of docking-based pharmacophores and comparison with other structure-based pharmacophore modeling methods
  55. Discovery of New Phosphoinositide 3-kinase Delta (PI3Kδ) Inhibitors via Virtual Screening using Crystallography-derived Pharmacophore Modelling and QSAR Analysis
  56. QSAR-guided pharmacophore modeling and subsequent virtual screening identify novel TYK2 inhibitor
  57. Degradability of chitosan micro/nanoparticles for pulmonary drug delivery
  58. Discovery of novel Flt3 inhibitory chemotypes through extensive ligand-based and new structure-based pharmacophore modelling methods
  59. The herbicide quinclorac as potent lipase inhibitor: Discovery via virtual screening and in vitro/in vivo validation
  60. Inhibition of dipeptidyl peptidase IV by fexofenadine: Virtual screening study
  61. Leader for anticancer
  62. Ligand-based modeling of Akt3 lead to potent dual Akt1/Akt3 inhibitor
  63. Synthesis and Structure-Activity Relationship; Exploration of some Potent Anti-Cancer Phenyl Amidrazone Derivatives
  64. Discovery of new Gyrase β inhibitors via structure based modeling
  65. Exploring the influence of culture conditions on kefir's anticancer properties
  66. Combining Stochastic Deformation/Relaxation and Intermolecular Contacts Analysis for Extracting Pharmacophores from Ligand–Receptor Complexes
  67. Ligand-based computational modelling of platelet-derived growth factor beta receptor leading to new angiogenesis inhibitory leads
  68. Novel nanoparticles based on chitosan-dicarboxylate conjugates via tandem ionotropic/covalent crosslinking with tripolyphosphate and subsequent evaluation as drug delivery vehicles
  69. Docking-based comparative intermolecular contacts analysis and in silico screening reveal new potent acetylcholinesterase inhibitors
  70. Simulated annealing molecular dynamics and ligand–receptor contacts analysis for pharmacophore modeling
  71. Computational modeling of the bat HKU4 coronavirus 3CLpro inhibitors as a tool for the development of antivirals against the emerging Middle East respiratory syndrome (MERS) coronavirus
  72. Unsupervised pharmacophore modeling combined with QSAR analyses revealed novel low micromolar SIRT2 inhibitors
  73. pharmacophore modelling
  74. Rosmarinic acid reverses the effects of metronidazole-induced infertility in male albino rats
  75. Discovery of novel potent nuclear factor kappa-B inhibitors (IKK-β) via extensive ligand-based modeling and virtual screening
  76. Combining molecular dynamics simulation and ligand-receptor contacts analysis as a new approach for pharmacophore modeling: beta-secretase 1 and check point kinase 1 as case studies
  77. Computer-aided discovery of new FGFR-1 inhibitors followed by in vitro validation
  78. Discovery of potent adenosine A2a antagonists as potential anti-Parkinson disease agents. Non-linear QSAR analyses integrated with pharmacophore modeling
  79. Novel anticancer compound [trifluoromethyl-substituted pyrazole N-nucleoside] inhibits FLT3 activity to induce differentiation in acute myeloid leukemia cells
  80. Pharmacophore and QSAR Modeling of Neuronal Nitric Oxide Synthase Ligands and Subsequent Validation and In Silico Search for New Scaffolds
  81. Cytotoxic activity of the novel heterocyclic compound G-11 is primarily mediated through intrinsic apoptotic pathway
  82. Discovery of new selective cytotoxic agents against Bcl-2 expressing cancer cells using ligand-based modeling
  83. Innovative computer-aided methods for the discovery of new kinase ligands
  84. Ligand-based modeling of diverse aryalkylamines yields new potent P-glycoprotein inhibitors
  85. Inhibitory Effects of New Mercapto Xanthine Derivatives in Human mcf7 and k562 Cancer Cell Lines
  86. QSAR studies in the discovery of novel type-II diabetic therapies
  87. Synthesis and characterization of chitosan-lactate–phthalate and evaluation of the corresponding zinc- and aluminum-crosslinked beads as potential controlled release matrices
  88. β-Caryophyllene as putative male contraceptive: enhances spermatogenesis but not spermiogenesis in albino rats
  89. Synthesis and evaluation of novel diphenylthiazole derivatives as potential anti-inflammatory agents
  90. Antiproliferative activity of the isoindigo 5′-Br in HL-60 cells is mediated by apoptosis, dysregulation of mitochondrial functions and arresting cell cycle at G0/G1 phase
  91. Combining docking-based comparative intermolecular contacts analysis and k-nearest neighbor correlation for the discovery of new check point kinase 1 inhibitors
  92. Ligand-based modeling followed by in vitro bioassay yielded new potent glucokinase activators
  93. The Anticancer Activity of the Substituted Pyridone-Annelated Isoindigo (5'-Cl) Involves G0/G1 Cell Cycle Arrest and Inactivation of CDKs in the Promyelocytic Leukemia Cell Line HL-60
  94. Tryptophan and thiosemicarbazide derivatives: design, synthesis, and biological evaluation as potential β-d-galactosidase and β-d-glucosidase inhibitors
  95. Enhanced drug encapsulation and extended release profiles of calcium–alginate nanoparticles by using tannic acid as a bridging cross-linking agent
  96. Discovery of nanomolar phosphoinositide 3-kinase gamma (PI3Kγ) inhibitors using ligand-based modeling and virtual screening followed by in vitro analysis
  97. Oleuropein potently inhibits mammalian target of rapamycin: possible involvement of tandem anomeric hyperconjugation–Michael reaction
  98. Ritodrine inhibits neuronal nitric oxide synthase, a potential link between tocolysis and autism
  99. The use of docking-based comparative intermolecular contacts analysis to identify optimal docking conditions within glucokinase and to discover of new GK activators
  100. Elaborate ligand-based modeling reveals new human neutrophil elastase inhibitors
  101. Synthesis and Antitumor Activities of Some NewN1-(Flavon-6-yl)amidrazone Derivatives
  102. Discovery of novel urokinase plasminogen activator (uPA) inhibitors using ligand-based modeling and virtual screening followed by in vitro analysis
  103. Elaborate ligand-based modeling coupled with QSAR analysis and in silico screening reveal new potent acetylcholinesterase inhibitors
  104. Design, Synthesis and Biological Evaluation of N4-Sulfonamido- Succinamic, Phthalamic, Acrylic and Benzoyl Acetic Acid Derivatives as Potential DPP IV Inhibitors
  105. Elaborate Ligand-Based Modeling Coupled with Multiple Linear Regression and k Nearest Neighbor QSAR Analyses Unveiled New Nanomolar mTOR Inhibitors
  106. Preparation andin vitrocharacterization of glibenclamide-loaded alginate hexyl-amide beads: a novel drug delivery system to improve the dissolution rate
  107. Synthesis and characterization of new derivatives of alginic acid and evaluation of their iron(III)-crosslinked beads as potential controlled release matrices
  108. Regression of endometrial implants treated with vitamin D3 in a rat model of endometriosis
  109. New leads for DPP IV inhibition: structure-based pharmacophore mapping and virtual screening study
  110. Sunitinib as an anti-endometriotic agent
  111. Synthesis of a Novel Chitosan-Based Polymer and Application as a Matrix for Controlled Drug Delivery
  112. Naproxen and Cromolyn as New Glycogen Synthase Kinase 3β Inhibitors for Amelioration of Diabetes and Obesity: An Investigation by Docking Simulation and Subsequent In Vitro/In Vivo Biochemical Evaluation
  113. Design, synthesis and structure–activity relationship of new HSL inhibitors guided by pharmacophore models
  114. Elaborate ligand-based modeling reveal new migration inhibitory factor inhibitors
  115. Pharmacophore modeling, homology modeling, and in silico screening reveal mammalian target of rapamycin inhibitory activities for sotalol, glyburide, metipranolol, sulfamethizole, glipizide, and pioglitazone
  116. β-Caryophyllene causes regression of endometrial implants in a rat model of endometriosis without affecting fertility
  117. Evaluation of naproxen and cromolyn activities against cancer cells viability, proliferation, apoptosis, p53 and gene expression of survivin and caspase-3
  118. Ligand-based pharmacophore exploration and QSAR analysis of transition state analogues followed by in silico screening guide the discovery of new sub-micromolar β-secreatase inhibitors
  119. Synthesis and biological activity assays of some new N1-(flavon-7-yl)amidrazone derivatives and related congeners
  120. Extensive ligand-based modeling and in silico screening reveal nanomolar inducible nitric oxide synthase (iNOS) inhibitors
  121. Application of docking-based comparative intermolecular contacts analysis to validate Hsp90α docking studies and subsequent in silico screening for inhibitors
  122. Famotidine inhibits glycogen synthase kinase-3β: An investigation by docking simulation and experimental validation
  123. Elaborate ligand-based modeling and subsequent synthetic exploration unveil new nanomolar Ca2+/calmodulin-dependent protein kinase II inhibitory leads
  124. Elaborate ligand-based modeling reveal new submicromolar Rho kinase inhibitors
  125. Effect of particle morphology and pore size on the release kinetics of ephedrine from mesoporous MCM-41 materials
  126. Design, synthesis, and biological evaluation of sulfonic acid ester and benzenesulfonamide derivatives as potential CETP inhibitors
  127. Ethosuximide and Phenobarbital Promote Wound Healing via Enhancing Collagenization
  128. Ligand-based modelling followed by synthetic exploration unveil novel glycogen phosphorylase inhibitory leads
  129. Discovery of New Antifungal Leads via Pharmacophore Modeling and QSAR Analysis of Fungal N‐Myristoyl Transferase Inhibitors Followed by In Silico Screening
  130. Thujone corrects cholesterol and triglyceride profiles in diabetic rat model
  131. Discovery of new nanomolar peroxisome proliferator-activated receptor γ activators via elaborate ligand-based modeling
  132. Discovery of new renin inhibitory leads via sequential pharmacophore modeling, QSAR analysis, in silico screening and in vitro evaluation
  133. Preparation of Silver- and Zinc-Doped Mullite-Based Ceramics Showing Anti-Bacterial Biofilm Properties
  134. Docking-Based Comparative Intermolecular Contacts Analysis as New 3-D QSAR Concept for Validating Docking Studies and in Silico Screening: NMT and GP Inhibitors as Case Studies
  135. Preparation of Polyester-Based Metal-Cross Linked Polymeric Composites as Novel Materials Resistant to Bacterial Adhesion and Biofilm Formation
  136. Rational exploration of new pyridinium-based HSP90α inhibitors tailored to thiamine structure
  137. Some sulfonamide drugs inhibit ATPase activity of heat shock protein 90: investigation by docking simulation and experimental validation
  138. Elaborate Ligand-Based Modeling Reveals New Nanomolar Heat Shock Protein 90α Inhibitors
  139. Discovery of novel CDK1 inhibitors by combining pharmacophore modeling, QSAR analysis and in silico screening followed by in vitro bioassay
  140. Discovery of new β-D-galactosidase inhibitors via pharmacophore modeling and QSAR analysis followed by in silico screening
  141. Discovery of new β-d-glucosidase inhibitors via pharmacophore modeling and QSAR analysis followed by in silico screening
  142. Elaborate ligand-based pharmacophore exploration and QSAR analysis guide the synthesis of novel pyridinium-based potent β-secretase inhibitory leads
  143. Discovery of new cholesteryl ester transfer protein inhibitors via ligand-based pharmacophore modeling and QSAR analysis followed by synthetic exploration
  144. Pharmacophore and QSAR modeling of estrogen receptor β ligands and subsequent validation and in silico search for new hits
  145. In Silico Screening for Non‐nucleoside HIV‐1 Reverse Transcriptase Inhibitors Using Physicochemical Filters and High‐Throughput Docking Followed by In Vitro Evaluation
  146. Inhibition of dipeptidyl peptidase IV (DPP IV) is one of the mechanisms explaining the hypoglycemic effect of berberine
  147. Homology modeling of MCH1 receptor and validation by docking/scoring and protein-aligned CoMFA
  148. Pharmacophore Modeling, Quantitative Structure−Activity Relationship Analysis, and Shape-Complemented in Silico Screening Allow Access to Novel Influenza Neuraminidase Inhibitors
  149. Docking Simulations and in Vitro Assay Unveil Potent Inhibitory Action of Papaverine against Protein Tyrosine Phosphatase 1B
  150. Discovery of DPP IV Inhibitors by Pharmacophore Modeling and QSAR Analysis followed by in silico Screening
  151. Development of predictive in silico model for cyclosporine- and aureobasidin-based P-glycoprotein inhibitors employing receptor surface analysis
  152. Inhibition of glycogen synthase kinase by curcumin: Investigation by simulated molecular docking and subsequentin vitro/in vivoevaluation
  153. Combining Ligand-Based Pharmacophore Modeling, Quantitative Structure−Activity Relationship Analysis and in Silico Screening for the Discovery of New Potent Hormone Sensitive Lipase Inhibitors
  154. Pharmacophore Modeling, Quantitative Structure–Activity Relationship Analysis, and in Silico Screening Reveal Potent Glycogen Synthase Kinase-3β Inhibitory Activities for Cimetidine, Hydroxychloroquine, and Gemifloxacin
  155. Olanzapine inhibits glycogen synthase kinase-3β: An investigation by docking simulation and experimental validation
  156. Discovery of new MurF inhibitors via pharmacophore modeling and QSAR analysis followed by in-silico screening
  157. Sodium lauryl sulfate impedes drug release from zinc-crosslinked alginate beads: Switching from enteric coating release into biphasic profiles
  158. Combining docking, scoring and molecular field analyses to probe influenza neuraminidase–ligand interactions
  159. Discovery of new potent human protein tyrosine phosphatase inhibitors via pharmacophore and QSAR analysis followed by in silico screening
  160. Effect of Ionic Crosslinking on the Drug Release Properties ofChitosan Diacetate Matrices
  161. Discovery of potent inhibitors of pseudomonal quorum sensing via pharmacophore modeling and in silico screening
  162. Synthesis and in vitro behavior of iron-crosslinked N-methyl and N-benzyl hydroxamated derivatives of alginic acid as controlled release carriers
  163. Berberine potently inhibits protein tyrosine phosphatase 1B: Investigation by docking simulation and experimental validation
  164. Effects of Variable Docking Conditions and Scoring Functions on Corresponding Protein-Aligned Comparative Molecular Field Analysis Models Constructed from Diverse Human Protein Tyrosine Phosphatase 1B Inhibitors
  165. Ligand-based assessment of factor Xa binding site flexibility via elaborate pharmacophore exploration and genetic algorithm-based QSAR modeling
  166. QSPR modeling of pseudoternary microemulsions formulated employing lecithin surfactants: Application of data mining, molecular and statistical modeling
  167. Development of quantitative structure–property relationship models for pseudoternary microemulsions formulated with nonionic surfactants and cosurfactants: application of data mining and molecular modeling
  168. Synthesis of iron-crosslinked chitosan succinate and iron-crosslinked hydroxamated chitosan succinate and their in vitro evaluation as potential matrix materials for oral theophylline sustained-release beads
  169. Spectrophotometric and Conductometric Study of the Complexation of Ranitidine to Fez+, Fe3+, Al*, Mg*+, Cu", Ni2+ and PtP+ Metal Ions: Pharmaceutical Implications
  170. N-Acyliminium ion cyclisation versus rearrangement. The synthesis of 13,13-dimethylberberines and 3,4-dimethylisoquinolin-1-ones
  171. The bis(homoallylic) stabilisation of an acyliminium ion and reactions with nucleophiles
  172. The Oxidation of Homophthalimide Derivatives by Dioxygen in Alkaline Media and Cleavage-Cyclisation Reactions
  173. A Concise Route to Tetrahydrophenanthridinones and Functionalised Isoquinolones